Bridge City Capital LLC Raises Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bridge City Capital LLC raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 94,471 shares of the medical instruments supplier's stock after acquiring an additional 6,430 shares during the quarter. LeMaitre Vascular comprises 2.3% of Bridge City Capital LLC's portfolio, making the stock its 5th largest position. Bridge City Capital LLC owned approximately 0.42% of LeMaitre Vascular worth $8,705,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of LeMaitre Vascular by 48.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after purchasing an additional 4,330 shares during the period. Townsquare Capital LLC boosted its holdings in LeMaitre Vascular by 38.0% during the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier's stock worth $4,454,000 after buying an additional 13,210 shares during the last quarter. Barclays PLC grew its holdings in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after purchasing an additional 29,180 shares during the period. Compass Planning Associates Inc acquired a new stake in shares of LeMaitre Vascular during the fourth quarter worth about $567,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in LeMaitre Vascular by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock worth $17,789,000 after purchasing an additional 11,395 shares during the period. Institutional investors own 84.64% of the company's stock.

Remove Ads

LeMaitre Vascular Price Performance

LMAT traded up $0.69 during trading on Thursday, hitting $85.21. The stock had a trading volume of 4,841 shares, compared to its average volume of 147,846. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 46.56, a P/E/G ratio of 2.22 and a beta of 0.89. The company has a 50 day moving average price of $93.67 and a 200-day moving average price of $94.41. LeMaitre Vascular, Inc. has a one year low of $62.39 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.94%. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LMAT shares. StockNews.com lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective for the company. Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $95.25.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.79% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.